Johnson & Johnson $JNJ Stock Bought by Mather Group LLC.

Mather Group LLC. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 21.3% in the 3rd quarter, Holdings Channel reports. The fund owned 81,293 shares of the company’s stock after acquiring an additional 14,250 shares during the period. Mather Group LLC.’s holdings in Johnson & Johnson were worth $21,522,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. West Wealth Group LLC raised its holdings in Johnson & Johnson by 837.5% in the third quarter. West Wealth Group LLC now owns 15,357 shares of the company’s stock valued at $4,066,000 after acquiring an additional 13,719 shares in the last quarter. First Pacific Financial boosted its stake in Johnson & Johnson by 18.3% during the 3rd quarter. First Pacific Financial now owns 26,468 shares of the company’s stock valued at $7,007,000 after acquiring an additional 4,087 shares during the last quarter. Cliftonlarsonallen Wealth Advisors LLC boosted its stake in Johnson & Johnson by 23.5% during the 3rd quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 39,674 shares of the company’s stock valued at $10,503,000 after acquiring an additional 7,547 shares during the last quarter. Fortitude Family Office LLC grew its holdings in Johnson & Johnson by 19.2% during the 3rd quarter. Fortitude Family Office LLC now owns 2,198 shares of the company’s stock worth $582,000 after acquiring an additional 354 shares in the last quarter. Finally, Harbor Group Inc. acquired a new position in Johnson & Johnson during the 3rd quarter worth $356,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance
• Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights
• Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend

Analysts Set New Price Targets

Several research firms have recently weighed in on JNJ. Argus set a $300.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Weiss Ratings raised shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $273.61.

Insiders Place Their Bets

In related news, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 over the last three months. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $253.49 on Thursday. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The company has a market cap of $610.89 billion, a PE ratio of 38.41, a P/E/G ratio of 2.54 and a beta of 0.21. The stock has a 50 day simple moving average of $265.80 and a 200-day simple moving average of $249.47. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.10 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.